Low expression of MDS1-EVI1–like-1 (MEL1) and EVI1-like-1 (EL1) genes in favorable-risk acute myeloid leukemia

This publication has 11 references indexed in Scilit:

• Breakpoints at 1p36.3 in three MDS/AML(M4) patients with t(1;3)(p36;q21) occur in the first intron and in the 5′ region of MEL1
  Genes, Chromosomes and Cancer, 2003
• Biallelic mutations in the CEBPA gene and low CEBPA expression levels as prognostic markers in intermediate-risk AML
  The Hematology Journal, 2003
• Favorable prognostic significance of CEBPA mutations in patients with de novo acute myeloid leukemia: a study from the Acute Leukemia French Association (ALFA)
  Blood, 2002
• High EVI1 expression predicts poor survival in acute myeloid leukemia: a study of 319 de novo AML patients
  Blood, 2002
• Improved prognostic significance of cytokine-induced proliferation in vitro in patients with de novo acute myeloid leukemia of intermediate risk: impact of internal tandem duplications in the Flt3 gene
  Leukemia, 2001
• Intergenic splicing of MDS1 and EVI1 occurs in normal tissues as well as in myeloid leukemia and produces a new member of the PR domain family.
  Proceedings of the National Academy of Sciences, 1996
• Activation of EVI1 gene expression in human acute myelogenous leukemias by translocations spanning 300-400 kilobases on chromosome band 3q26.
  Proceedings of the National Academy of Sciences, 1992
• Interleukin-1 stimulates proliferation of acute myeloblastic leukemia cells by induction of granulocyte-macrophage colony-stimulating factor release
  Blood, 1989
• Fucose binding lectin for characterizing acute myeloid leukemia progenitor cells
  Blood, 1986
• Proposed Revised Criteria for the Classification of Acute Myeloid Leukemia
  Annals of Internal Medicine, 1985